These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18519405)

  • 1. Maintenance treatment in multiple myeloma.
    Harousseau JL
    Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
    [No Abstract]   [Full Text] [Related]  

  • 2. New treatments in multiple myeloma: beyond optimal treatment.
    Harousseau JL
    Ann Oncol; 2008 Jul; 19 Suppl 5():v68-70. PubMed ID: 18611904
    [No Abstract]   [Full Text] [Related]  

  • 3. Diagnosis and the current trends in multiple myeloma therapy.
    Dmoszyńska A
    Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent progress in diagnosis of and therapy for multiple myeloma].
    Okamoto S
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1922-31. PubMed ID: 17037337
    [No Abstract]   [Full Text] [Related]  

  • 5. [A cure for multiple myeloma?].
    Harousseau JL
    Presse Med; 2006 Sep; 35(9 Pt 2):1288-90. PubMed ID: 16969322
    [No Abstract]   [Full Text] [Related]  

  • 6. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma.
    Kyle RA; Rajkumar SV
    N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
    [No Abstract]   [Full Text] [Related]  

  • 8. Frontline treatment of multiple myeloma.
    Fonseca R
    Hematology; 2012 Apr; 17 Suppl 1():S101-4. PubMed ID: 22507793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and therapy of multiple myeloma.
    Palumbo A; Cerrato C
    Korean J Intern Med; 2013 May; 28(3):263-73. PubMed ID: 23682217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide for bortezomib-resistant multiple myeloma.
    Briani C; Berno T; Campagnolo M; Zambello R
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906
    [No Abstract]   [Full Text] [Related]  

  • 11. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel agents for multiple myeloma treatment.
    Ribatti D; Vacca A
    Curr Pharm Biotechnol; 2006 Dec; 7(6):395. PubMed ID: 17168654
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple myeloma.
    Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
    Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide efficacy in bortezomib-resistant myeloma.
    Gozzetti A; Crupi R; Defina M; Bocchia M
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of newly diagnosed multiple myeloma.
    Palumbo A; Magarotto V; Larocca A; Bringhen S; Falco P; Di Raimondo F; Baldini L; Boccadoro M
    Curr Hematol Malig Rep; 2008 Apr; 3(2):107-14. PubMed ID: 20425454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
    Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R; San Miguel J; Ludwig H; Bergsagel L; Blade J; Lonial S; Anderson KC; Tosi P; Sonneveld P; Sezer O; Vesole D; Cavo M; Einsele H; Richardson PG; Durie BG; Rajkumar SV;
    Blood; 2009 Aug; 114(9):1729-35. PubMed ID: 19561323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
    Burke MJ; George E; Adler AI
    Lancet Oncol; 2015 May; 16(5):492-3. PubMed ID: 25818587
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel agents in the frontline management of multiple myeloma.
    Loong HH
    Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
    Yaqub S; Ballester G; Ballester O
    Cancer Invest; 2013 Oct; 31(8):529-37. PubMed ID: 24083815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.